



## **CRISPR Therapeutics to Present at the Annual Barclays Global Healthcare Conference**

March 2, 2017

BASEL, Switzerland and CAMBRIDGE, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR-Cas9 gene-editing technology into transformative medicines, today announced that Rodger Novak, M.D., Chief Executive Officer and Founder of CRISPR Therapeutics, will present at the Annual Barclays Global Healthcare Conference on Thursday, March 16th at the Loews Miami Beach Hotel, Miami, FL.

Event: Annual Barclays Global Healthcare Conference

Date: Thursday, March 16th

Time: 8:00 AM ET

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors & Media section of the Company's website at [www.crisprtx.com](http://www.crisprtx.com).

### **About CRISPR Therapeutics**

CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR / Cas9 gene-editing platform. CRISPR / Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company's multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR / Cas9 patent estate for human therapeutic use was licensed from the Company's scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit [www.crisprtx.com](http://www.crisprtx.com).

### **MEDIA CONTACTS:**

Jennifer Paganelli  
W2O Group for CRISPR  
347-658-8290 [jpaganelli@w2ogroup.com](mailto:jpaganelli@w2ogroup.com)

### **INVESTOR CONTACT:**

Chris Brinzey  
Westwicke Partners for CRISPR  
339-970-2843 [chris.brinzey@westwicke.com](mailto:chris.brinzey@westwicke.com)



CRISPR Therapeutics AG